Alright! Who will they sell their remaining doses to?
The numbers (77% of vaccinations were with the BioNTech vaccine) suggest that they are doing just fine with the much more expensive but less controversial option.
Which is cool, but some countries are just looking for raw vaccine for now, no matter which one it is.
The numbers (77% of vaccinations were with the BioNTech vaccine) suggest that they are doing just fine with the much more expensive but less controversial option.
Which is cool, but some countries are just looking for raw vaccine for now, no matter which one it is.